ω 3 pufas breast and prostate cancer experimental studies
Báo cáo y học: "Can a single model explain both breast cancer and prostate cancer?" pps
... Page 12 of 13 (page number not for citation purposes) Theoretical Biology and Medical Modelling 2007, 4:28 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 Prostate Cancer Cells ... Protects Prostate Cancer Cells from Apoptosis in Vitro and Confers Resistance to Androgen Depletion in Vivo Cancer Res 1995, 55:4 438 -4445 López-Otín C, Diamandis EP: Breast and Prostate Cancer: ... the Normal Breast and Breast Cancer J Steroid Biochem Mol Biol 1997, 61:281-286 Risbridger GP, Bianco JJ, Ellem SJ, McPherson SJ: Oestrogens and prostate cancer Endocr Relat Cancer 20 03, 10:187-191...
- 13
- 330
- 0
Nutrition, Exercise and Prostate Cancer potx
... of Contents Nutrition, Exercise and Prostate Cancer Introduction Understanding the Links Between Nutrition, Exercise, and Prostate Cancer Effects of Oxidation and Inflammation The Contribution ... understanding of the roles of diet and exercise in the prevention of age-related diseases, as well as in the recurrence and progression of prostate cancer Nutrition, Exercise and Prostate Cancer ... Exercise and Prostate Cancer tissue that is removed surgically, and have found that inflammation leads to the atrophy, or wasting away, of normal prostate tissue adjacent to precancerous and cancerous...
- 32
- 285
- 0
báo cáo khoa học: " Platinum resistance in breast and ovarian cancer cell lines Niels Eckstein" pptx
... regimen for advanced breast cancer ER-positive breast cancers are the most prevalent form of the disease Breast cancer patients with extensive lymph node involvement (advanced breast cancer) have a ... 1964, 239 :34 36-44 Eckstein Journal of Experimental & Clinical Cancer Research 2011, 30 :91 http://www.jeccr.com/content /30 /1/91 28 Muller EG: Thioredoxin deficiency in yeast prolongs S phase and ... Res 1992, 20 :38 21 -30 34 Xanthoudakis S, Miao G, Wang F, Pan YC, Curran T: Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme EMBO J 1992, 11 :33 23- 35 35 Saitoh M,...
- 11
- 373
- 0
PROSTATE CANCER – ORIGINAL SCIENTIFIC REPORTS AND CASE STUDIES pdf
... from prostate cancer, one case (no 30 ) was not diagnosed before death, and the cause of death is known from the death certificate only (DCO) 35 83. 6 34 83. 0 33 32 31 30 81.2 78.9 78.1 76 .3 29 ... 1990-19 93 14,728 6, 933 1994-1997 11,441 6, 536 1998-2001/5 8,224 5,150 15+ - 40.0 (17.0; 15-97) 32 .4 (19.8; 0-1 03) Males 38 .4 (16.0; 15- 93) 30 .9 (19.0; 0-95) Females 41.5 (17.7; 15-97) 33 .8 (20.4; ... compare cancer incidence of the Saarland Aussiedler cohort to the Saarland population The Saarland Cancer Registry provided data on Saarland population figures and number of cancer cases (Saarland Cancer...
- 238
- 411
- 2
Báo cáo khoa học: "In vitro studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol" pot
... radiation and endocrine therapy in breast cancer Endocr Relat Cancer 20 03, 10 :37 5 -38 8 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 Villalobos M, Becerra D, Nunez MI, Valenzuela MT, Shiles ... in prostate cancer Clin Prostate Cancer 2005, 4:124-129 Kaufmann WK: Human topoisomerase II function, tyrosine phosphorylation and cell cycle checkpoints Proc Soc Exp Biol Med 1998, 217 :32 7 -33 4 ... 2000, 38 : 635 - 639 Sasaki M, Tanaka Y, Perinchery G, Dharia A, Kotcherguina I, Fujimoto S, Dahiya R: Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer...
- 12
- 368
- 0
Báo cáo y học: "High-Resolution Flow Cytometry: a Suitable Tool for Monitoring Aneuploid Prostate Cancer Cells after TMZ and TMZ-BioShuttle Treatment"
... Wachsmuth M, Waldeck W, Friedrich E, and Debus J A biological transporter http://www.medsci.org Int J Med Sci 2009, 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 for the delivery of peptide ... Murray T, Xu J, and Thun MJ Cancer statistics 2007 CA Cancer J Clin 2007; 57: 43- 66 Li Y, and Cozzi PJ Targeting uPA/uPAR in prostate cancer Cancer Treat Rev 2007 ;33 (6):521-7 Catalona WJ and Smith ... (Amst) 2009; 8: 11 53- 1165 50 Shimada M and Nakanishi M DNA damage checkpoints and cancer J Mol Histol 2006; 37 : 2 53- 260 51 Damia G and Broggini M Cell cycle checkpoint proteins and cellular response...
- 10
- 408
- 0
Tài liệu Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study pdf
... 89 6.76 3. 43 0.51 0 .39 –0.66 68 50 57 38 25 26 6.70 6.28 7 .33 3. 77 3. 10 3. 33 0.56 0.49 0.45 0 .37 –0.85 0.29–0.81 0.27–0.74 History of LCIS No Yes 157 18 81 6.41 12.99 3. 30 5.69 0.51 0.44 0 .39 –0.68 ... Yes 152 23 86 6.44 10.11 3. 61 1. 43 0.56 0.14 0.42–0. 73 0. 03 0.47 5-y predicted breast cancer risk, % ഛ2.00 2.01 3. 00 3. 01–5.00 ജ5.01 35 42 43 55 13 29 27 20 5.54 5.18 5.88 13. 28 2.06 3. 51 3. 88 4.52 ... 1590 39 6 2.8 36 .5 30 .6 24.1 6.0 159 2422 2 031 1571 39 3 2.4 36 .8 30 .9 23. 9 6.0 Race White Black Other 635 9 111 129 96.4 1.7 2.0 634 7 109 120 96.5 1.7 1.8 No of first-degree relatives with breast cancer...
- 18
- 645
- 0
Prostate cancer: diagnosis and treatment docx
... Problems 7 10 3. 1 3. 2 3. 3 3. 4 Diagnosis and Staging of Prostate Cancer When to Biopsy Histological Diagnosis Staging Classification for Prostate Cancer Nomograms 13 13 15 16 20 4.1 4.2 4 .3 4.4 4.5 ... series and Welsh Cancer Intelligence unit and Surveillance (WCISU) Between 1996 and 2004 the age standardised incidence rate of prostate cancer increased in all cancer networks in England and Wales1 ... Localised Prostate Cancer Introduction Predictive Factors and Risk Groups Treatment Decision Making Initial Treatment Options Managing Adverse Effects of Treatment Follow-up 23 23 23 24 24 33 37 5.1...
- 146
- 485
- 0
Prostate cancer - Diagnosis and treatment pot
... 1.1 Communication and support 1.2 Diagnosis and staging of prostate cancer 1 .3 Localised prostate cancer 10 1.4 Managing adverse effects of treatment 13 1.5 Managing relapse ... of clinically insignificant prostate cancer) and benefits of prostate biopsy 1.2 .3 If the clinical suspicion of prostate cancer is high, because of a high PSA value and evidence of bone metastases ... reliability, validity and limitations of the prediction NICE clinical guideline 58 – Prostate cancer 1 .3 Localised prostate cancer Men with high-risk localised prostate cancer (see table 1) may...
- 41
- 365
- 0
Questions & Answers About Prostate Cancer, Bone Metastases, and Treatment-Related Osteoporosis pot
... with prostate cancer and 27,050 men will die from prostate cancer in the U.S Q How is prostate cancer diagnosed? A Prostate cancer is most often diagnosed by needle biopsy of the prostate gland ... urinary bladder in men Q How common is prostate cancer? A Prostate cancer is the most common form of cancer in men (except for skin cancer) and a leading cause of cancer death worldwide In 2007, close ... General Information about Prostate Cancer Q What is prostate cancer? A Prostate cancer is an abnormal (malignant) growth of the prostate, a walnut-sized gland at the base of the urinary...
- 8
- 335
- 0
Báo cáo khoa học: Altered expression of tumor protein D52 regulates apoptosis and migration of prostate cancer cells potx
... and proliferation in the host tissue [31 ] The expression of several genes, such as CARD10 [32 ] and Vav3 [33 ], and integrins is important in determining the formation of metastatic cells [34 ,35 ] ... Card10 is a novel caspase FEBS Journal 275 (2008) 57 03 57 13 ª 2008 The Authors Journal compilation ª 2008 FEBS R Ummanni et al 33 34 35 36 37 38 39 40 41 42 recruitment domain ⁄ membrane-associated ... (2004) Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer Cancer Res 64, 38 14 38 22 Wang R, Xu J, Saramaki O, Visakorpi T, Sutherland WM, Zhou J, Sen B, Lim SD, Mabjeesh...
- 11
- 444
- 0
prostate cancer, methods and protocols
... and Henderson, B E (1981) A cohort study of mortality from cancer of the prostate in Catholic priests Br J Cancer 43, 233 – 235 63 Colditz, G (1996) Consensus conference: smoking and prostate cancer ... the prostate of prostate cancer cell lines or by growing Human Prostate Cancer 23 Table Profile of Established Human Prostate Cancer and Immortalized Cell Lines Cell line PC- 93 PC -3 AD primary prostate ... H-ras) Silent mutation of p 53 + Low levels of functional p 53 ++ References 18 19,92 20, 93 50 21,92 24,92 29 30 30 32 22 + + + + NR NR NR NR NR NR NR – 34 ,35 34 ,35 36 43 + NR NR 44 + NR NR + NR...
- 395
- 395
- 0
báo cáo hóa học:" Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer" pptx
... 8.0 4 .3 11.5 10.1 10.4 6.6 4 +3 3 +3 4 +3 3+4 4+5 4 +3 3+5 3+ 4 3+ 4 4+4 3+ 3 3+ 4 4 +3 3+4 3+ 4 Pathologic stage AMACR expression CTL induction Peptide specificity T2aN0M0 T2aN0M0 T2bN0M0 T3aN0M0 T3aN0M0 ... all three prostate cancer cell lines (LNCaP, DU145 and PC -3) and in surgically resected prostate cancer tissues (Figure 1B and 1C) Low levels of expression were detected in non-cancerous prostate ... Immunother 2007, 56:689-698 http://www.translational-medicine.com/content/7/1/1 03 23 24 25 26 27 28 29 30 31 32 33 34 35 36 Alves PM, Faure O, Graff-Dubois S, Cornet S, Bolonakis I, Gross DA, Miconnet...
- 11
- 531
- 0
Báo cáo hóa học: "A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899" pot
... 100% 12 30 39 % 97% 25 62 40% 98% Lung 13% 13% 13% Liver 9% 10% 10% Bone 28 88% 29 94% 57 90% Bone Marrow 0% 3% 2% Pleura 3% 0% 2% Other Prior Treatment 11 34 % 29% 20 32 % Orchiectomy 10 31 % 23% 17 ... = 31 ) n Percent Total (n = 63) n Percent Age Median 70 65 68 50-89 Range 45-80 45-89 Race White 30 94% 28 90% 58 Black 3% 10% 92% 6% Hispanic ECOG PS 3% 0% 2% 15 47% 17 55% 32 51% 16 50% 12 39 % ... Orchiectomy 10 31 % 23% 17 27% Prostatectomy 17 53% 15 48% 32 51% Other Surgery 19 59% 20 65% 39 62% Radiation Therapy 18 56% 20 65% 38 60% Hormonal Therapy 31 97% 29 94% 60 95% 13% 6% 10% Extent of Disease...
- 9
- 462
- 0
Báo cáo hóa học: " Copy number and gene expression differences between African American and Caucasian American prostate cancer" docx
... (1q31 .3, 1q44, 3q26.1, 4q 13. 2, 5q 33. 1, 7q35, 11p15.4, 17q21 .31 , and 20p 13) , while 12 showed significant gains in AA compared to CA patients (1p36. 13, 5p15 .33 , 5q35 .3, 8p11. 23, 14q24 .3, 14q32 .33 , ... advanced-stage prostate cancer: the Prostate Cancer Outcomes Study J Natl Cancer Inst 2001, 93: 388 -39 5 Albano JD, Ward E, Jemal A, Anderson R, Cokkinides VE, Murray T, Henley J, Liff J, Thun MJ: Cancer ... advanced prostate cancer Cancer 2009, 115 :36 70 -36 79 29 Saramaki OR, Porkka KP, Vessella RL, Visakorpi T: Genetic aberrations in prostate cancer by microarray analysis Int J Cancer 2006, 119: 132 2- 132 9...
- 9
- 372
- 0
báo cáo hóa học: " Urinary and sexual outcomes in long-term (5+ years) prostate cancer disease free survivors after radical prostatectomy" ppt
... 0.077 -0.258 0.012 0.0 53 0.612 -0.207 0.046 -0.096 0 .35 9 SB* 0.098 0 .35 0 0.161 0.124 0.1 43 0.170 -0.064 0.5 43 -0.015 0.889 -0. 031 0.771 SF# 1.841 0 .30 3 / -3. 138 0.056 / -12. 530 0.027 / Significant ... -0.298
- 8
- 318
- 0
Báo cáo sinh học: "Multiplex Zymography Captures Stage-specific Activity Profiles of Cathepsins K, L, and S in Human Breast, Lung, and Cervical Cancer" potx
... Cathepsins K, L, and S in Human Breast, Lung, and Cervical Cancer Binbin Chen and Manu O Platt* Abstract Background: Cathepsins K, L, and S are cysteine proteases upregulated in cancer and proteolyze ... mobility and renaturation properties Methods: Frozen breast, lung, and cervix cancer tissue lysates and normal organ tissue lysates from the same human patients were obtained (28 breast tissues, 23 ... tool for breast cancer A) Normal and tumor breast tissue zymograms were compared for patient-to-patient variation Standard dose curves of recombinant cathepsin K (0.2, 0.5, 1, and ng) and cathepsin...
- 13
- 382
- 0
Báo cáo sinh học: "Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer" docx
... http://www.translational-medicine.com/content/9/1/ 133 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 during mitogenesis: requirement for insulin- and lysophosphatidic acidmediated signal transduction Mol ... dual PI3K/ mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations Cancer Res 2008, 68:8022-8 030 45 Carracedo A, Pandolfi PP: The PTEN-PI3K ... Medical Page of 10 Oncology, Yale Cancer Center, Yale University, 33 3 Cedar St, New Haven, CT 06520, United States of America 3Department of Pathology, Yale University, 33 3 Cedar St, New Haven, CT 06520,...
- 10
- 300
- 0
Tìm thêm: xác định các mục tiêu của chương trình khảo sát chương trình đào tạo gắn với các giáo trình cụ thể xác định thời lượng học về mặt lí thuyết và thực tế tiến hành xây dựng chương trình đào tạo dành cho đối tượng không chuyên ngữ tại việt nam điều tra đối với đối tượng giảng viên và đối tượng quản lí điều tra với đối tượng sinh viên học tiếng nhật không chuyên ngữ1 khảo sát thực tế giảng dạy tiếng nhật không chuyên ngữ tại việt nam khảo sát các chương trình đào tạo theo những bộ giáo trình tiêu biểu nội dung cụ thể cho từng kĩ năng ở từng cấp độ xác định mức độ đáp ứng về văn hoá và chuyên môn trong ct các đặc tính của động cơ điện không đồng bộ hệ số công suất cosp fi p2 đặc tuyến mômen quay m fi p2 đặc tuyến tốc độ rôto n fi p2 đặc tuyến dòng điện stato i1 fi p2 động cơ điện không đồng bộ một pha sự cần thiết phải đầu tư xây dựng nhà máy phần 3 giới thiệu nguyên liệu chỉ tiêu chất lượng theo chất lượng phẩm chất sản phẩm khô từ gạo của bộ y tế năm 2008 chỉ tiêu chất lượng 9 tr 25